STRATEGIC ADVISORY BOARD
DEBRA WOLGEMUTH Ph.D. – Professor, Department of Genetics & Development and Obstetrics & Gynecology, The Center for Reproductive Sciences, and The Institute of Human Nutrition, Columbia University Dr. Wolgemuth is co-inventor of the use of cyclin A2 modulation in cardiovascular disease and is an internationally recognized investigator with an illustrious career in developmental biology and genetics. Her laboratory discovered mammalian cyclin A1, a gene that plays crucial roles in meiosis and several types of leukemia. She has received multiple awards and serves on numerous leading academic boards. She received master’s degrees from Vanderbilt and Columbia, her Ph.D. from Columbia and continued her post-doctoral work at Sloan-Kettering and Rockefeller University.
JUDITH L. SWAIN, M.D. – Dr. Judith L. Swain is currently the Executive Director of the Singapore Institute for Clinical Sciences within A*STAR, and the Lien Ying Chow Professor of Medicine at the Yong Loo Lin School of Medicine, National University of Singapore. Her past appointments include Dean for Translational Medicine at the University of California, San Diego; Chair of the Department of Medicine at Stanford University where she held the Arthur Bloomfield and George E. Becker Professorships; and as Professor of Genetics, and Director of Cardiovascular Medicine at the University of Pennsylvania where she was the Herbert C. Rorer Professor of Medical Sciences. She trained in Internal Medicine and Cardiovascular Medicine at Duke University and then joined the faculty there where she became widely known in the field of molecular cardiology, and pioneered the use of transgenic animals to understand the genetic basis of cardiovascular development and disease. Dr. Swain has served in a number of national leadership roles including President of the American Society for Clinical Investigation, and President of the American Association of Physicians. She serves or has served as a director or a SAB member for a number of biomedical technology companies, and is co-founder of Synecor, LLC a medical device accelerator company. She has been elected to a number of honorary societies including the Association of American Physicians, the American Society for Clinical Investigation, Fellow of the American Association for the Advancement of Science, and the Institute of Medicine.
ROXANA MEHRAN, M.D. FACC, FACP, FCCP, FESC, FAHA, FSCAI – is Professor of Medicine (Cardiology) and Health Evidence and Policy and Director of Interventional Cardiovascular Research and Clinical Trials at Mount Sinai School of Medicine, New York, NY. She completed her training in Internal Medicine at University of Connecticut and served as chief medical resident before completing cardiology and interventional cardiology fellowships at Mount Sinai Medical Center. Dr. Mehran is internationally recognized for her work in multicenter, multinational clinical trials, specializing in complex data analysis. She has developed several risk scores for bleeding and acute kidney injury. Previously (2004-2010), Dr. Mehran was Associate Professor of Medicine and Director of Outcomes Research, Data Coordinating and Analysis at the Center of Interventional Vascular Therapies at Columbia University. She is reknowned for her vast experience working with regulatory agencies to design and conduct clinical trials. She is currently one of several lead investigators who collaborate with the FDA to develop standard definitions for clinical trials in cardiovascular disease. She is Chief Scientific Officer at the Cardiovascular Research Foundation for the past 12 years, Co-director of the Transcatheter Cardiovascular Therapeutics (TCT) meeting for the past 15 years, and an editorial board member of multiple cardiovascular journals. She has served on the board of trustees of the Society of Cardiac Angiography and Interventions (SCAI), program committee of the American Heart Association, writing committee of the ACC/AHA PCI guidelines. She is currently on the board of directors for Harboring Hearts and program chair for SCAI- Women in Innovation (WIN) Initiative.
HOWARD B. JOHNSON – is an entrepreneurial executive with breadth of experience developed over 30 years in operations, finance, investor relations and venture capital, primarily in bioscience companies. He started his career as an investment banker working on large product development financings for leading biotech companies (e.g. Genentech, Amgen, Centocor, and, Genzyme). He then became founding investor and board member of Acorda Therapeutics, now publicly traded with an approved product for multiple sclerosis. He also founded and ran a medical device company developing laparoscopic instruments for incontinence surgery. Starting in 1999, he was an executive officer of public small cap companies, including: from 1999-2001 as CFO of an internet services company with $23 million in annual revenues; and, from 2002-2010 as President and CFO of an oncology drug development company that advanced from filing an IND to filing an NDA for its lead product for acute myelogenous leukemia. At this company, he managed several functional areas, including pre-commercial operations, regulatory, manufacturing, business development, finance and human resources. He was also responsible for major contract and license negotiations, raised over $140 million in financing, and ran investor relations. Most recently, he has been investing in and developing new products for obesity and diabetes.
FARHAN SHARAFF – is a professional with over 25 years experience in investment managment. He has worked and lived on five continents having held jobs as Chief Investment Officer at Citigroup, Zurich Scudder, Cigna Corporation and at Guggenheim Partners. He has extensive knowledge of the equity markets and has conducted analysis of companies, sectors and markets. He holds a degree in electronic engineering and an MBA. Her presently resides in Rye, New York.